271 DNA and RNA alterations associated with colorectal peritoneal metastases: A systematic review 2021, 10, 8876–8882. https://doi.org/10.1002/ cam4.4400. [51] Zihui Yong, Z.; Ching, G.T.H.; Ching, M.T.C. Metastatic Profile of Colorectal Cancer: Interplay Between Primary Tumor Location and KRAS Status. J. Surg. Res. 2020, 246, 325–334. https:// doi.org/10.1016/j.jss.2018.11.025. [52] Prasanna, T.; Wong, R.; Price, T.; Shapiro, J.; Tie, J.; Wong, H.L.; Nott, L.; Roder, D.; Lee, M.; Kosmider, S.; et al. Metastasectomy and BRAF mutation; an analysis of survival outcome in metastatic colorectal cancer. Curr. Probl. Cancer 2021, 45, 100637. https://doi.org/10.1016/j.currproblcancer.2020.100637. [53] Oh, H.H.; Joo, Y.E. Novel biomarkers for the diagnosis and prognosis of colorectal cancer. Intest. Res. 2020, 18, 168–183. https://doi. org/10.5217/ir.2019.00080. [54] Caputo, F.; Santini, C.; Bardasi, C.; Cerma, K.; Casadei-Gardini, A.; Spallanzani, A.; Andrikou, K.; Cascinu, S.; Gelsomino, F. BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights. Int. J. Mol. Sci. 2019, 20, 5369. https://doi. org/10.3390/ijms20215369. [55] Sinicrope, F.A.; Shi, Q.; Smyrk, T.C.; Thibodeau, S.N.; Dienstmann, R.; Guinney, J.; Bot, B.M.; Tejpar, S.; Delorenzi, M.; Goldberg, R.M.; et al. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. Gastroenterology 2015, 148, 88–99. https://doi. org/10.1053/j.gastro.2014.09.041. [56] Argilés, G.; Tabernero, J.; Labianca, R.; Hochhauser, D.; Salazar, R.; Iveson, T.; Laurent-Puig, P.; Quirke, P.; Yoshino, T.; Taieb, J.; et al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2020, 31, 1291–1305. https://doi. org/10.1016/j.annonc.2020.06.022. [57] Janakiraman, M.; Vakiani, E.; Zeng, Z.; Pratilas, C.A.; Taylor, B.S.; Chitale, D.; Halilovic, E.; Wilson, M.; Huberman, K.; Ricarte Filho, J.C.; et al. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res. 2010, 70, 5901–5911. https://doi. org/10.1158/0008-5472.Can-10-0192. [58] De Roock, W.; Claes, B.; Bernasconi, D.; De Schutter, J.; Biesmans, B.; Fountzilas, G.; Kalogeras, K.T.; Kotoula, V.; Papamichael, D.; Laurent-Puig, P.; et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis. Lancet Oncol. 2010, 11, 753–762. https://doi.org/10.1016/ s1470-2045(10)70130-3. [59] Popat, S.; Hubner, R.; Houlston, R.S. Systematic review of microsatellite instability and colorectal cancer prognosis. J. Clin. Oncol. 2005, 23, 609–618. https://doi.org/10.1200/ jco.2005.01.086. [60] Segelman, J.; Granath, F.; Holm, T.; Machado, M.; Mahteme, H.; Martling, A. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br. J. Surg. 2012, 99, 699–705. https://doi.org/10.1002/bjs.8679. [61] Arjona-Sánchez, A.; Barrios, P.; Boldo-Roda, E.; Camps, B.; Carrasco-Campos, J.; Concepción Martín, V.; García-Fadrique, A.; Gutiérrez-Calvo, A.; Morales, R.; Ortega-Pérez, G.; et al. HIPECT4: Multicentre, randomized clinical trial to evaluate safety and efficacy of Hyperthermic intra-peritoneal chemotherapy (HIPEC) with Mitomycin C used during surgery for treatment of locally advanced colorectal carcinoma. BMC Cancer 2018, 18, 183. https://doi.org/10.1186/ s12885-018-4096-0. [62] Sorich, M.J.; Wiese, M.D.; Rowland, A.; Kichenadasse, G.; McKinnon, R.A.; Karapetis, C.S. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: A meta-analysis of randomized, controlled trials. Ann. Oncol. 2015, 26, 13–21. https://doi.org/10.1093/annonc/ mdu378. [63] Graf, W.; Cashin, P.H.; Ghanipour, L.; Enblad, M.; Botling, J.; Terman, A.; Birgisson, H. Prognostic Impact of BRAF and KRAS Mutation in Patients with Colorectal and Appendiceal Peritoneal Metastases Scheduled for CRS and HIPEC. Ann. Surg. Oncol. 2020, 27, 293–300. https://doi. org/10.1245/s10434-019-07452-2. [64] Shendure, J.; Ji, H. Next-generation DNA sequencing. Nat. Biotechnol. 2008, 26, 1135– 1145. https://doi.org/10.1038/nbt1486. [65] Kukurba, K.R.; Montgomery, S.B. RNA Sequencing and Analysis. Cold Spring Harb. Protoc. 2015, 2015, 951–969. https://doi.org/10.1101/pdb. top084970. [66] Damodaran, S.; Berger, M.F.; Roychowdhury, S. Clinical tumor sequencing: Opportunities and challenges for precision cancer medicine. Am. Soc. Clin. Oncol. Educ. Book 2015, 35, e175–e182. https://doi.org/10.14694/EdBook_ AM.2015.35.e175. [67] Alorda-Clara, M.; Torrens-Mas, M.; Morla-Barcelo, P.M.; Martinez-Bernabe, T.; Sastre-Serra, J.; Roca, P.; Pons, D.G.; Oliver, J.; Reyes, J. Use of Omics Technologies for the Detection of Colorectal Cancer Biomarkers. Cancers 2022, 14, 817. https://doi.org/10.3390/cancers14030817. 11
RkJQdWJsaXNoZXIy MTk4NDMw